Activated platelets can promote tumor cell invasion into healthy tissue

Pre-clinical studies conducted by CCR investigators and colleagues show that platelets, tiny cells that promote blood clotting, when activated by the CD97 protein on the surface of tumor cells, enable the tumor cells to invade healthy tissue and then metastasize. The study, published April 17, 2018, in Cell Reports, was led by Kathleen Kelly, Ph.D., Chief, Laboratory of Genitourinary Cancer PathogenesisRead more...

Target with bullseye

Two-Day Symposium - Frontiers in Targeting MYC: Expression, Regulation and Degradation

Dec 12, 2017

There is a need for the global community to come together to discuss modern approaches for studying and targeting MYC. Frontiers in Targeting MYC: Expression, Regulation and Degradation is a two-day symposium that will enable the Myc community to come together to discuss problems, approaches and recent results in targeting Myc. Learn more...

RNA interactions in viral infections

2018 RNA Interactions in Viral Infections Workshop

Dec 12, 2017

For more than 70 years, the study of viruses has been at the forefront of molecular biology and cancer biology. Studies done with viruses have provided the foundations of RNA biology including RNA capping, RNA splicing, RNA polyadenylation, RNA transport, cap-independent RNA translation and RNA instability. This workshop will provide a forum in which the most recent progress in protein-RNA interactions in virus infections will be discussed. Learn more...

Anupama Khare, Ph.D.

Anupama Khare joins CCR as NIH Stadtman Investigator

Dec 12, 2017

Anupama Khare, Ph.D. has joined the Laboratory of Molecular Biology as a Stadtman Tenure Track Investigator. Dr. Khare's research focuses on understanding how different microbial species co-exist in the same environmental niche and what the molecular interactions in such communities are. She is also interested in studying antibiotic persistence and identifying novel bacterial pathways that can be targeted for antimicrobial therapy in investigating the genetic basis of complex bacterial behaviors in natural environments, with an overarching goal of identifying novel targets for antibiotic therapies. Learn more...

Mouse bladder

Researchers studying alternative to bladder removal for bladder cancer patients

Dec 11, 2017

A new phase I clinical trial conducted by researchers at the Center for Cancer Research (CCR) is evaluating the safety and tolerability, or the degree to which any side effects can be tolerated by patients, of a two-drug combination as a potential alternative to bladder removal for bladder cancer patients. The trial targets patients with non-muscle invasive bladder cancer (NMIBC) whose cancers have stopped responding to traditional therapies. Read more...

Researchers studying alternative to bladder removal for bladder cancer patients
Everyday health logo

CCR scientists featured in Cancer Special Report 2017 from Everyday Health

Dec 7, 2017

In a recent article from Everyday Health, Elizabeth DeVita-Raeburn, Senior Editor of Oncology, details cancer trends in diagnosis, stages, treatment and survival rates. DeVita was one of 12 journalists selected by the Association of Health Care Journalists to attend a week-long reporting fellowship at the National Cancer Institute (NCI) in November 2017 to learn about the latest cancer research and participate in guided tours of NCI wards and labs. Her “Cancer Special Report 2017” discusses the latest immunology work of Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, and Stephanie Goff, M.D., Staff Clinician in the Surgery Branch, gene-expression profiling technique of Louis Staudt, M.D., Ph.D., Co-Chief of the Lymphoid Malignancies Branch, and new Cancer Moonshot efforts to address rare cancers, spearheaded by Mark Gilbert, M.D., Chief of the Neuro-Oncology Branch. Read the full story…

Michael Becker

Walking with purpose after an HPV-related head and neck cancer diagnosis

Dec 6, 2017

In November 2015, Michael Becker was diagnosed with Stage IV head and neck cancer caused by a strain of the human papillomavirus, or HPV. He now advocates for education and awareness of the HPV vaccine as cancer prevention for both boys and girls. “I want to make people aware that you can avoid my situation by getting the shot.” Read more…

Walking with purpose after an HPV-related head and neck cancer diagnosis
Foregut Team

Members of NIH Foregut Team discuss new treatment options for stomach cancer

Dec 4, 2017

On Wednesday, Nov. 29, 2017, NIH Foregut Team members presented information and answered questions during a webinar on stomach cancer treatment options. Jeremy Davis, M.D., Staff Clinician in the CCR Thoracic and Gastrointestinal Oncology Branch, and Theo Heller, M.D., Senior Investigator in the National Institute of Diabetes and Digestive and Kidney Diseases, joined David Fogel, a recent total gastrectomy patient, to discuss the latest advancements in treatment. The webinar, “Navigating New Treatment Options for Gastric Cancer: Reaching above and beyond the standard of care,” was facilitated by the NIH Clinical Center and Inspire, a social network for health that connects patients and caregivers in a safe, permission-based manner. Access the recorded webinar.

Prostate cancer

Clinical trial tests precision radiotherapy for recurrent prostate cancer

Dec 4, 2017

CCR investigators are leading a trial of stereotactic body radiation therapy (SBRT) to treat localized prostate cancer that has recurred after standard radiation therapy. The technique uses advanced molecular imaging to guide the delivery of high doses of radiation just to tumors that have recurred, potentially leading to fewer side effects. Read more…

Clinical trial tests precision radiotherapy for recurrent prostate cancer
Leukemia cells

New immunotherapy approach leads to remission in patients with the most common type of childhood cancer

Nov 30, 2017

Chimeric antigen receptor (CAR) T-cell immunotherapy has emerged as a promising treatment for pre-B cell acute lymphoblastic leukemia (B-ALL), the most common type of childhood cancer. B-ALL is characterized by an overproduction of immature white blood cells called lymphoblasts. In a trial led by Center for Cancer Research investigators, around 70 to 90 percent of patients whose B-ALL has relapsed or developed resistance to chemotherapy entered remission after CAR T-cell therapy targeting CD19. Read more…

New immunotherapy approach leads to remission in patients with the most common type of childhood cancer
Dr. Claudia Palena

Claudia Palena appointed as tenured senior investigator

Nov 27, 2017

Claudia Palena, Ph.D., has been appointed as a tenured senior investigator in the Laboratory of Tumor Immunology and Biology (LTIB). Dr. Palena’s laboratory focuses on the immunological targeting of drivers of tumor dissemination and resistance to therapy. Her recent work identified the novel tumor antigen brachyury as a key factor in epithelial to mesenchymal transition (EMT), a process associated with cancer progression. More recently, Dr. Palena’s efforts have been aimed at investigating immunotherapeutic approaches that may be used alone or in combination with anti-neoplastic agents to disrupt tumor metastasis and resistance to therapy.